• Total indicated underground mineral resources of 3.17 million tonnes at Camp and Los Cuyes deposits, containing 0.37 million gold equivalent ounces at a cutoff grade of 2.2 g/t AuEq.
• Total inferred underground mineral resources of 12.1 Mt at Camp and Los Cuyes deposits, containing 1.50 million gold equivalent ounces at a cutoff grade of 2.2 g/t AuEq. Ongoing 3,500-metre drill program set to expand known mineralization zones.
• Preliminary Economic Assessment for underground operation expected by year-end 2025.
• El Domo Project development on track with detailed cost breakdown and construction timeline targeting 2026 production.

Silvercorp Metals (NYSE-A: SVM) (TSX: SVM), a Canadian mining company producing silver, gold, lead, and zinc with a long history of profitability, has announced an updated mineral resource estimate (“MRE”) for its Condor Project, located in Ecuador’s Zamora-Chinchipe Province.

The new estimate, effective as of Feb. 28, 2025, was prepared by SRK Consulting (Canada) Inc., in accordance with National Instrument 43-101 standards, and marks the first step in Silvercorp’s effort to reposition Condor as a high-grade underground gold project (https://ibn.fm/J4HYK). An updated Preliminary Economic Assessment (“PEA”) is expected later this year. The project was previously envisioned as a low-grade, bulk-tonnage open pit, which would have been costly to develop and challenging to permit.

The update centers on the Camp and Los Cuyes deposits. At a cut-off grade of 2.2 g/t AuEq, indicated resources included 3.17 million tonnes at an average grade of 3.58 g/t AuEq, totaling 0.37 million ounces. Additionally, inferred resources included 12.1 million tonnes grading 3.84 g/t AuEq, totalling 1.50 million ounces AuEq.

Metallurgical testing yielded favorable gold recoveries: up to 96% at Camp and 88% at Los Cuyes based on cyanide leaching.

Although the underground strategy dominates the current outlook, Silvercorp also reported open-pit constrained resources at the Soledad and Enma deposits. These include 0.15 million ounces AuEq in the indicated category and 0.38 million in the inferred category, at cut-off grades of 0.5 g/t for Soledad and 0.6 g/t for Enma.

The Condor Project is located in a volcanic complex that intrudes older granodiorite rocks, where gold and silver mineralization is consistent with a low to intermediate sulphidation epithermal system. Mineralization styles vary across the deposits, including sub-vertical sulfide-bearing veins and wider zones of disseminated mineralization.

Gold is primarily associated with pyrite and sphalerite, with smaller amounts of galena and chalcopyrite. These characteristics shape the company’s ongoing exploration targets and development scenarios.

To advance the project, Silvercorp has launched a 3,500-metre (10 holes) surface drilling campaign in May 2025, testing areas where the company sees exploration potential. Drilling will focus on:

• Broad zones of sub-horizontal disseminated gold mineralization in rhyolitic tuffs at Los Cuyes.
• Contact zones between rhyolite domes and batholith granodiorite at Camp for wide mineralization.
• Gap areas between Camp, Soledad, Los Cuyes, and Enma deposits, testing for potential connection and strike extension of mineralized structures.

In parallel, Silvercorp is advancing a PEA for an underground operation at Condor, expected by the end of 2025. The company is also working to secure the permits and community agreements required to develop underground exploration tunnels which it is planning to build in 2H 2026.

The Condor update follows Silvercorp’s recent construction budget announcement for the El Domo Project, also in Ecuador. The company expects to bring El Domo into production by the end of 2026 at a revised cost of $240.5 million, below the 2021 feasibility estimate of $247.6 million (https://ibn.fm/bd01V).

The development has been divided into several stages, each with its own budget and timeline:

• Package #1: Site Preparation and Infrastructure – $47.5 million: Earthworks began earlier this year, with full site readiness targeted by Q4 2025.
• Package #2: Open Pit Mining and Stripping – $39 million: This stage will begin in August 2025. It involves producing 43,000 tonnes of ore by end-2026 and creating a ready-to-mine inventory of 550,000 cubic metres of ore to support three years of production.
• Package #3: Processing Plant and Equipment – $33 million: Engineering and equipment selection is being led by China’s Jinpeng Group, with construction slated to begin in September 2025.

Additionally, Silvercorp has signed a power line agreement with Ecuador’s state utility CNEL EP. Construction is set to begin in the summer of 2025, with an estimated completion time of 13–17 months. Final costs and contractor selections are still pending. In response to Ecuador’s seasonal power supply instability, Silvercorp has sourced diesel power generators to provide backup electricity. These will be operational before the process plant comes online.

Silvercorp’s ongoing investment in Ecuador reflects its long-term strategy to generate shareholder value through high-quality assets, free cash flow from established operations, and disciplined project development. With a portfolio that includes multiple projects in Ecuador and China, the company has an 18-year track record of profitability and remains focused on ensuring organic growth through extensive drilling for discovery; ongoing merger and acquisition efforts; and an unwavering commitment to responsible mining and ESG.

For more information, visit the company’s website at www.silvercorpmetals.com/welcome.

Third-Party Content Disclaimer

The IBN website may contain third-party content articles and other content submitted by third parties, including articles submitted through the IBN Premium Partnership Program. All opinions, statements and representations expressed by such third parties are theirs alone and do not express or represent the views and opinions of IBN or its affiliates and owners. Content created by third parties is the sole responsibility of such third parties, and IBN does not endorse, guarantee or make representations concerning the accuracy and completeness of any third-party content. You acknowledge that by IBN providing you with this internet portal that makes accessible to you the ability to view third party content through the IBN site, IBN does not undertake any obligation to you as a reader of such content or assume any liability relating to such third-party content. IBN expressly disclaims liability relating to such third-party content. IBN and its members, affiliates, successors, assigns, officers, directors, and partners assume no responsibility or liability that may arise from the third-party content, including, but not limited to, responsibility or liability for claims for defamation, libel, slander, infringement, invasion of privacy and publicity rights, fraud, or misrepresentation, or an private right of action under the federal securities laws of the United States or common law. Notwithstanding the foregoing, IBN reserves the right to remove third-party content at any time in its sole discretion. By viewing this third-party content, you acknowledge that you have viewed, read fully, accepted and agreed to all terms of the Disclaimer at https://IBN.fm/Disclaimer.

Dynamic Global Events (“DGE”) is proud to announce the 6th Clinical Trial Agreements Summit taking place August 21-22 in Philadelphia. This event will explore how to negotiate budgetary restraints, protect intellectual property and clinical data, and reduce risks in indemnification and subject injury.

This summit offers a dynamic mix of panel discussions, fireside chats, solo presentations, and exclusive networking opportunities with top stakeholders across the clinical research industry. Hear from 30+ expert speakers representing leading organizations including Merck, Pfizer, Takeda, Alkermes, and many more.

As clinical trial agreements form the foundation of every collaboration between sponsors, sites, and CROs, it’s essential to stay ahead of evolving expectations and negotiation strategies. The 6th Clinical Trial Agreements Summit is your chance to gain actionable insights, sharpen your skills, and walk away with tools to drive smarter, faster deal-making.

Register now to secure your spot at the 6th Clinical Trial Agreements conference!

To learn more, please visit https://ibn.fm/AqgPJ

• Nevada’s Walker Lane area is becoming a prime target for mineral exploration
• Lahontan Gold is focused on becoming a strategic player in the Walker Lane region
• Lahontan’s strategic execution, focused on resource growth and economic evaluation, mirrors the broader resurgence of Walker Lane as a target-rich environment
• LGCXF recently launched new metallurgical testing at its Santa Fe deposit, aiming at improving gold and silver mineralization

Nevada’s Walker Lane region has emerged as one of North America’s most compelling gold and silver frontiers — and Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF) is strategically placed to capitalize on that fact, owning and developing four high-potential exploration properties in the area. With a vision to evolve into Nevada’s premier silver and gold producer, Lahontan has built a robust portfolio of distillery-scale assets across this geologically diverse and historically rich trend.

Walker Lane spans roughly 500 miles along the California/Nevada border. The area “is rapidly becoming a prime target for mineral exploration, offering investors a unique blend of proven production history and untapped potential,” reports a recent Investing News Network article (ibn.fm/Tebop). “This geological corridor along the California-Nevada border is experiencing a resurgence, driven by recent discoveries, advanced exploration techniques, a strong precious metals market and growing demand for domestic metal supply. The Walker Lane Trend’s combination of geological richness, a favorable jurisdiction and strategic importance in North American mineral resources presents a compelling case for investors seeking high-reward opportunities in a relatively low-risk environment,” the article continued. 

The region remains notably underexplored compared to Nevada’s prolific Carlin Trend, though it has produced more than 40 million ounces of gold, nearly one-fifth of the state’s total output, and is renowned for deposits like Comstock and Round Mountain that often include significant silver and copper byproducts (ibn.fm/3VxDH). This rich geological backdrop, combined with Nevada’s supportive permitting environment, which is rated second globally in the 2023 Fraser Institute Mining Survey, has reignited interest among explorers and major miners alike.

Recent activity in Walker Lane has provided clear evidence of its rediscovery as a mining hotspot. Modern exploration methods and increased capital availability are fueling renewed drilling and mapping programs, translating Walker Lane’s complex geology into a diverse pipeline of future discoveries.

Lahontan Gold is focused on becoming a strategic player in the Walker Lane region. The company controls four flagship properties in the heart of Walker Lane: Santa Fe, West Santa Fe, Moho and Redlich (ibn.fm/mAxF3). The company’s flagship project, the Santa Fe Mine, is a 26.4 km2 past-producing, oxide-hosted gold-silver property. Between 1988 and 1995, Santa Fe produced 356,000 ounces of gold and 784,000 ounces of silver via open-pit mining and heap-leach processing. Since 2021, Lahontan has drilled 13,118 meters across 50 holes, contributing to a pit-constrained NI 43-101 resource estimate of 1.539 million indicated ounces and 0.411 million inferred ounces of gold equivalent (ibn.fm/Gdknh).

In recent news, Lahontan initiated a new round of metallurgical testing focused on the transition metallurgical domain at its Santa Fe location. The company intends to evaluate advanced heap-leach methods and reagents aimed at boosting gold and silver recoveries – which could significantly improve project economics. CEO, Executive Chair, and Founder Kimberly Ann emphasized that this testing could have a positive impact on recoveries and project value.

Lahontan’s resource base is supported by a robust Preliminary Economic Assessment completed in December 2024, which shows a pre-tax NPV5 of $265 million and internal rate of return (“IRR”) of 41% using $2,705/oz gold (ibn.fm/IalVD). This evaluation lays the groundwork for further development, including planned 2025 drill programs aimed at both expanding Santa Fe’s resource and testing satellite zones at West Santa Fe.

The Moho project adds underground potential, with historical sampling and drilling yielding high grades, some more than 20 g/t gold equivalent, while the Redlich property shows significant silver endowment, highlighted by a historic 16.5 million-ounce AgEq estimate, and new discoveries such as the DBK vein system, which returned up to 17 g/t AgEq over thick intervals (ibn.fm/9hdVx). This diversified portfolio offers exposure to multiple deposit types within a single, highly prospective geological trend.

Lahontan’s strategic execution, focused on resource growth and economic evaluation, mirrors the broader resurgence of Walker Lane as a target-rich environment. The company emphasizes streamlined permitting paths and the value of a Nevada-based, brownfield-friendly approach, with infrastructure and support assets favoring rapid project progression in a tier 1 jurisdiction. 

Lahontan Gold Corp.’s portfolio reflects the opportunity that Nevada’s Walker Lane presents: a blend of historical production, strategic exploration and near-term development potential. With a flagship project primed to enter evaluation, high-grade satellite projects awaiting follow-up drilling, and a proven team driving forward in one of the world’s most investor-friendly mining jurisdictions, Lahontan is well-positioned to emerge as the district’s next gold and silver success story.

For more information, visit the company’s website at www.LahontanGoldCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to LGCXF are available in the Company’s newsroom at ibn.fm/LGCXF

• Despite the critical importance of rare earth element metals, the United States has long been dependent on imports to provide an adequate supply.
• Ucore has secured a $18.4 million funding agreement from the U.S. DoD to support the development of its rare earth processing facility in Louisiana. 
• Ucore CEO notes that the funding validates the company’s technological leadership, underscores the strategic value of domestic REE processing. 

As global competition intensifies over the control and supply of critical minerals, the United States is taking aggressive steps to secure domestic sources of rare earth elements (“REEs”)—materials essential for defense systems, electronics and clean energy. A recent announcement from Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) highlights a significant milestone in this effort. The company has secured a $18.4 million funding agreement from the U.S. Department of Defense (“DoD”) to support the development of Ucore’s rare earth processing facility in Louisiana. The project represents a major step toward American independence in the global REE supply chain, which is currently dominated by China.

Rare earth elements are indispensable to modern technology. From fighter jets and guided missile systems to electric vehicles and smartphones, these materials form the backbone of numerous advanced applications. Despite the critical importance of these metals, the United States has long been dependent on imports, with China supplying more than 70% of the world’s rare earths and processing an even larger share. This heavy reliance poses serious national security and economic risks. According to a U.S. geological survey, China accounted for nearly 60% of rare earth mining output in 2023, while the United States produced just 12% and lacks sufficient processing infrastructure to compete globally (https://ibn.fm/ErIqO).

The implications of this dependency are profound. In recent years, China has shown a willingness to wield its control over REEs as a geopolitical weapon. In 2010, it restricted rare earth exports to Japan during a diplomatic dispute, and similar export restrictions have resurfaced amid the ongoing U.S.-China trade tensions. As recently as 2023, Beijing imposed curbs on the export of critical metals like gallium and germanium, signaling its continued readiness to leverage mineral dominance for strategic influence (https://ibn.fm/XsmU0). These actions have prompted bipartisan calls in Washington for bolstering domestic mining, refining, and recycling capacity.

The federal government has responded by committing billions of dollars through the Defense Production Act and the Inflation Reduction Act to expand domestic supply chains for critical minerals. In this context, Ucore’s agreement with the DoD stands out as a meaningful implementation of these policies. Announced earlier this month, the $18.4 million in initial construction funding will support the development of Ucore’s Strategic Metals Complex (“SMC”) in Alexandria, Louisiana—a facility that aims to become a cornerstone of American rare earth processing capability (https://ibn.fm/lnb9K).

The SMC will utilize Ucore’s Proprietary RapidSX(TM) technology, which offers a more efficient and environmentally sustainable alternative to conventional solvent extraction methods. The company expects the facility to begin commissioning in 2025, with commercial production starting in 2026. Once operational, the SMC will be capable of processing up to 2,000 metric tons of total rare earth oxides (“TREO”) per year, scaling to 5,000 tons annually in subsequent phases (https://ibn.fm/mXeNr). The plant is designed to separate both light and heavy REEs, including neodymium, praseodymium, dysprosium and terbium, which are crucial for permanent magnets used in electric motors and defense systems.

Ucore CEO Pat Ryan emphasized that the DoD funding validates the company’s technological leadership and underscores the strategic value of domestic REE processing. “Ucore’s business model is founded on 1) collaboration with an array of like-minded upstream and downstream commercial and governmental partners, and 2) the implementation of the next logical leap in commercial critical metals separation technology resulting from Western innovation,” Ryan stated. “Ucore is very appreciative to the U.S. DOD for the opportunity, and potential future opportunities, which have now resulted in this dedicated expansion project to full-scale processing production.

“This U.S. DOD Louisiana SMC funding agreement is a critical step for Ucore’s commercial advancements,” Ryan continued, “but more importantly, for the progression of a Western rare earth supply chain, and North American critical metals security, which cannot exist without competitive critical metals processing on the world stage.”

The agreement includes milestone-based disbursements and covers a portion of the SMC’s total estimated cost, with additional financing anticipated from private and federal sources.

As the global landscape for critical minerals continues to evolve, Ucore Rare Metals is emerging as a key player in America’s strategic push to reduce reliance on foreign sources. With government backing, advanced technology and a clear roadmap to commercialization, the company is positioned to play a vital role in reshaping the rare earth supply chain. In an era defined by technological rivalry and geopolitical uncertainty, such efforts are not just economically important but also imperative for national security. 

For more information, visit www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• NGTF combines AI-powered robotics technology with strategic hotel acquisitions, expanding into new vision for next-generation hospitality solutions
• Recent executive appointments have brought decades of hotel operations expertise and supply chain innovation to accelerate the company’s deployment
• Major hotel advancements, including a LOI to acquire a $36.93 million Hilton Garden Inn deal adjacent to Disney’s Cotino development, to position NGTF as a flagship automation showcase

The hospitality industry stands at a technological crossroads. With shortages continuing to challenge hotel operations and guests demanding enhanced service experiences, the sector faces unprecedented pressure to innovate. Traditional staffing models are proving inadequate, with many properties struggling to maintain service standards while controlling costs. This disruption has created a massive opportunity for niche curiosities to evolve into proven hospitality assets.

Enter Nightfood Holdings (OTCQB: NGTF), a company uniquely positioned to scale up this transformation through its integrated approach of AI-powered robotics deployment and strategic hotel ownership.

Executive Leadership Drives Automation Strategy

NGTF’s recent leadership appointments signal a serious commitment to scaling its hospitality automation platform. Jimmy Chan, the company’s new CEO, brings over 20 years of entrepreneurial expertise, including founding CarryOutSupplies.com, one of North America’s largest custom-printed foodservice packaging providers and now a business of Nightfood. His deep understanding of hospitality supply chains and operational optimization directly aligns with NGTF’s mission to streamline hotel operations through technology.

Ried Floco, appointed as President and Director, adds three decades of executive leadership across the hospitality sector, having overseen more than 200 hotel properties with $3 billion in combined asset valuations. His experience spans top-tier brands including Marriott, Hilton, Intercontinental, and Starwood Hotels, providing NGTF with the operational insight needed to successfully integrate robotics into real-world hotel environments.

This executive team combines technical expertise to deploy automation solutions with hospitality experience to ensure they enhance rather than disrupt guest experiences.

Real Estate Meets Robotics Innovation

NGTF’s strategy distinguishes itself through asset-backed automation deployment. Rather than simply selling robotics solutions to third parties, the company owns and operates the hotels where its technology is implemented, creating multiple revenue streams while demonstrating real-world performance.

The company’s recent execution of a Letter of Intent (“LOI”) to acquire the 125-room Hilton Garden Inn in Rancho Mirage, California, exemplifies this approach. Located adjacent to Disney’s Cotino development, a 618-acre residential resort community, this property offers both immediate revenue generation and long-term appreciation potential. More importantly, it serves as a high-visibility showcase for NGTF’s Robotics-as-a-Service platform under a major hospitality brand.

Market Timing and Industry Transformation

The hospitality automation market is experiencing explosive growth. Market research indicates the global service robotics market is estimated to grow to almost $108 Billion by 2030.

Technology is transforming operational efficiency through robotic housekeeping solutions, a major addressing matter the industry’s labor challenge. The increased demand for hotel automation, driven by staff shortages, is leading to greater use of robotic services for tasks ranging from room sweeping to food and amenity delivery.

Vertical Integration Advantage

Through its acquisitions of Skytech Automated Solutions and CarryOutSupplies.com, combined with its RoboOps365 division, NGTF has created a comprehensive platform spanning robotics development, hospitality supply chain management, and hotel operations. This vertical integration allows the company to optimize every aspect of hotel automation, from the technology itself to the supplies and services that support it.

The company’s approach creates a feedback loop where operational insights from its owned properties directly inform robotics development, ensuring solutions address real-world hospitality challenges rather than theoretical applications.

The company’s ability to demonstrate ROI through its own operations while building a scalable platform for broader industry adoption could establish NGTF as a leader in the hospitality automation revolution.

For more information, visit the company’s website at NightfoodHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF

• The company announced the groundbreaking of its Louisiana Strategic Metals Complex (“SMC”) in Alexandria.
• The Louisiana SMC is designed to utilize Ucore’s proprietary RapidSX(TM) technology.
• Ucore also announced the execution of $18.4 million in funding from the U.S. Department of Defense (“DoD”).

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a critical metals technology company developing scalable rare earth element (“REE”) refining infrastructure in North America, has marked a significant milestone in the development of a domestic REE supply chain. The company announced the groundbreaking of its Louisiana Strategic Metals Complex (“SMC”) in Alexandria (https://ibn.fm/zPMiw). This facility represents the company’s first commercial REE refining operation and is poised to play a pivotal role in reducing North America’s reliance on foreign sources for critical minerals.

The Louisiana SMC is designed to utilize Ucore’s proprietary RapidSX(TM) technology, an advanced solvent extraction process that offers a more efficient and environmentally friendly method for separating REEs (https://ibn.fm/DbX2R). This technology has demonstrated the capability to process REEs at least three times faster than conventional solvent extraction methods, resulting in a significantly smaller physical footprint and reduced environmental impact.

The facility, located at the England Airpark in Alexandria, spans some 80,800 square feet and is strategically positioned to process high-purity rare earth oxides from mixed rare earth chemical concentrates obtained from multiple global feedstock sources. The initial production capacity is planned at 2,000 tonnes per annum (“tpa”) of total rare earth oxides (“TREO”), with expansions to 5,000 tpa by 2026 and 7,500 tpa by 2027.

The U.S. Department of Defense (“DoD”) has recognized the strategic importance of the Louisiana SMC by providing $18.4 million in funding to accelerate the installation of the RapidSX technology at the facility (https://ibn.fm/I2A8o). This investment underscores the DoD’s commitment to strengthening the domestic supply chain for critical minerals essential to national security and technological advancement.

Ucore’s focus on the Louisiana SMC aligns with broader efforts to establish a secure and independent REE supply chain in North America. By leveraging innovative technologies and strategic partnerships, the company aims to mitigate the risks associated with foreign dependence for these vital materials. The facility’s development is a testament to Ucore’s commitment to pioneering solutions that address the growing demand for REEs in various industries, including defense, renewable energy, and electric vehicles.

While the Louisiana SMC remains Ucore’s primary focus, the company continues to advance its Bokan-Dotson Ridge project in southeast Alaska (https://ibn.fm/U4YlX). This project, which hosts the highest-grade heavy rare earth element (“HREE”) resource in the United States, is envisioned as a long-term source of HREEs to complement the feedstock for the Louisiana facility. Ucore’s strategic approach ensures that the Bokan project progresses without detracting from the immediate priorities associated with the Louisiana SMC.

The groundbreaking of the Louisiana SMC represents a significant step forward in Ucore’s mission to establish a resilient and sustainable REE supply chain in North America. Through the deployment of cutting-edge technologies and strategic collaborations, Ucore is poised to play a leading role in meeting the critical mineral needs of the future.

For more information, visit www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• The new FDA voucher program aims to speed approval of drugs aligned with national health priorities.
• NRX-100, a preservative-free ketamine, is also under an Abbreviated New Drug Application (“ANDA”) with a priority review request.
• NRx has submitted full CMC data and draft labeling for NRX-100, meeting key Commissioner’s National Priority Voucher pre-qualification criteria.
• The company’s U.S.-based manufacturing aims to reduce foreign supply chain dependence and address diversion concerns.
• A patent on the preservative-free process and a citizen petition to withdraw preserved ketamine could bolster NRx’s market position.

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company developing innovative treatments for suicidal depression and PTSD, is accelerating its push toward regulatory approval of NRX-100, a preservative-free intravenous ketamine formulation. The company has filed an application under the newly created FDA Commissioner’s National Priority Voucher (“CNPV”) program, which promises significantly shortened review timelines for drugs that meet urgent U.S. health priorities (https://ibn.fm/VeYud).

The new CNPV program, announced by FDA Commissioner Marty Makary on June 17, is intended to bring promising treatments to market more quickly. Makary had previously identified psychedelic drugs for treatment of suicidal depression and PTSD as a national priority. For eligible drugs, the program compresses the final review timeline from roughly 10–12 months down to 1–2 months. This streamlined pathway will be available to a limited number of companies aligned with public health priorities such as addressing the health crisis in the U.S., increasing domestic drug manufacturing, and the development of more innovative treatments.

NRX-100 appears to fit that profile. Developed as a preservative-free formulation of ketamine, the drug targets severe psychiatric conditions that have received renewed national attention. Suicide and PTSD have been highlighted by federal officials, including the U.S. president and Cabinet members, as areas requiring urgent intervention.

NRx emphasized that it has already submitted the Chemistry, Manufacturing, and Controls (“CMC”) portion of the application and received an FDA information request, which it has addressed. The company also submitted proposed labeling and reports stability and sterility data that suggest a three-year shelf life at room temperature, an important logistical benefit for hospital and clinical settings.

Jonathan C. Javitt, MD, MPH, Chairman and CEO of NRx, said the CNPV aligns with the company’s strategy. “As previously determined by FDA, our products are innovative treatments that address the current health crisis of suicidal depression and PTSD, and address an unmet medical need,” Javitt explained. “The FDA’s announcement has now validated our company’s focus on manufacturing and CMC by identifying CMC as a pre-requisite to the CNPV program. The timelines announced for the CNPV program are consistent with NRx’s previous guidance of FDA decisions (PDUFA date) by year-end 2025.”

In parallel, the company has filed an Abbreviated New Drug Application (“ANDA”) for NRX-100 with a request for priority review. The two pathways, CNPV and ANDA, are expected to complement one another, according to the company. Should the CNPV be granted, the drug could enter a Commissioner-led review program with integrated oversight from key FDA offices.

The formulation also has manufacturing and market advantages. NRX-100 is produced domestically in West Columbia, South Carolina, addressing concerns over reliance on international ketamine supply chains. The company has added anti-diversion measures to limit misuse, an important step in addressing the growing scrutiny around ketamine’s off-label use.

To further solidify its market position, NRx is pursuing a citizen petition to withdraw preservative-containing versions of ketamine, citing toxicity from benzethonium chloride. If successful, this could clear regulatory space for NRX-100 while reinforcing its safety claims. The company has also filed a patent on its preservative-free manufacturing process.

Ketamine is already approved for anesthesia and has seen expanded use in off-label psychiatric treatment. The current generic ketamine market, valued at around $750 million, is projected to grow to $3–5 billion by 2033. A preservative-free product with clear regulatory backing could appeal to both hospital buyers and psychiatric treatment centers seeking safer and more standardized formulations.

The FDA previously granted Fast Track designation to NRX-101, a combination therapy of NRX-100 and another compound, further indicating regulatory interest in the company’s approach to treating high-risk psychiatric conditions.

For more information, visit the company’s website at www.NRxPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP

AI World Society Circle (“AIWS”) is proud to announce the San Francisco Chapter of its flagship After Hours AI World Society Circle event. This exclusive evening experience will offer a unique opportunity for attendees to connect with fellow AI enthusiasts, industry leaders, and innovators in a relaxed and positive atmosphere. It will offer unrivaled networking opportunities, engaging discussions, expert insights, as well as AI start-up pitches, allowing attendees to stay ahead of the curve on all matters AI.

AIWS is a global initiative dedicated to promoting ethical AI governance and responsible AI development. It is an institution that believes in the power of community-driven innovation, with regional chapters designed to bring together diverse perspectives and expertise to explore the challenges and opportunities posed by AI. Ever since its inception, AIWS has launched and established a presence in major global tech hubs, including Los Angeles, New York, Silicon Valley, Atlanta, Toronto, London, and Amsterdam.

The San Francisco Chapter will draw on the lessons learned from previous events, all of which have been lauded for providing excellent networking opportunities. They have also received high praise for the value they offer attendees from a knowledge perspective, with many noting how integral the events have been to their staying ahead in an industry that is quickly evolving.

With thought-provoking discussions and unrivaled networking opportunities, attendees of the After Hours AI World Society Circle have a chance to be part of the global AI discourse and shape the future of AI governance, ensuring that emerging technologies align with human values and respect for human rights.

To learn more, please visit https://ibn.fm/u558O

• Lantern Pharma uses a proprietary AI platform, RADR^®, to guide its oncology drug development, enabling rapid drug candidate identification and targeted trial design based on genomic and biomarker data.
• A Phase 2 trial patient achieved a complete response in their primary cancer lesions after multiple prior therapies failed and has remained responsive to LP-300 for two years signaling durable clinical benefit in this challenging population.
• The target population, never-smokers with non-small cell lung cancer, represents a growing global unmet need estimated at over $4 billion annually.

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, recently reported an encouraging clinical outcome in its Phase 2 HARMONIC(TM) trial, where a patient with advanced non-small cell lung cancer (“NSCLC”) achieved a complete response using LP-300, a compound optimized through Lantern’s AI-powered platform, RADR(R) (https://ibn.fm/II6O6).

This outcome is particularly notable because the patient had previously undergone three unsuccessful lines of treatment, including immunotherapy and targeted kinase inhibitors. The patient’s sustained remission, now over two years, highlights the potential of AI-powered drug development to identify novel therapeutic opportunities for difficult-to-treat cancers.

RADR(R), short for Response Algorithm for Drug Positioning & Rescue, is Lantern’s proprietary platform for integrating large-scale genomic, biomarker, and preclinical data. The system is designed to uncover drug-cancer matches and synergistic combinations faster and more cost-effectively than traditional approaches. It was instrumental in advancing LP-300 by confirming its potential mechanism of action and compatibility with existing chemotherapy regimens.

In the HARMONIC(TM) trial, LP-300 is being tested in combination with pemetrexed and carboplatin, targeting never-smoker NSCLC patients who have progressed after prior kinase inhibitor therapy. The trial is randomized, open-label, and enrolling patients in the U.S., Japan, and Taiwan. With approximately 90 participants planned, the study compares LP-300 plus chemotherapy against chemotherapy alone.

The early signals are encouraging. Lantern’s lead-in cohort showed an 86% clinical benefit rate and a 43% objective response rate. In one case, a 70-year-old never-smoker with advanced disease showed a 57% tumor volume reduction in 2024. By early 2025, imaging confirmed a complete response in both lung and adrenal lesions. No dose-limiting toxicities or significant adverse reactions were reported over 21 cycles of treatment.

“This outcome provides important confirmation of our data and AI-driven approach to drug development and gives us growing confidence as we advance toward potential future registration-enabling studies for this underserved patient population that has no approved treatment options after failing targeted kinase therapies,” said Lantern CEO Panna Sharma, commenting on the results. “This remarkable case exemplifies several of the things we have hoped to observe with LP-300 in the HARMONIC trial. To see a heavily pre-treated patient not only achieve a complete response in their target cancer lesions but maintain that response with excellent quality of life is truly extraordinary,” Sharma added.

The never-smoker NSCLC population is clinically distinct. It has grown significantly over the past 30 years, from 15% to over 25% of lung cancer cases globally. In East Asia, never-smokers account for nearly 35% of new NSCLC diagnoses. Yet, no therapies are approved specifically for this subset of patients, despite the distinct molecular drivers and limited treatment options after failure of kinase targeted therapies. Lantern estimates this group represents a global market opportunity exceeding $4 billion annually.

RADR(R) was built to address exactly this kind of niche: genetically defined cancers with unmet needs. By leveraging machine learning, computationally-driven mechanistic biology, and biomarker discovery, Lantern is not only identifying drug candidates but also helping design trials that focus on populations most likely to benefit. According to the company, RADR(R) has processed over 200 billion oncology-specific data points to date, enabling the advancement of multiple clinical programs.

In addition to LP-300, Lantern’s pipeline includes two other small molecule candidates (LP-184, in a Phase 1a trial for advanced solid tumors and glioblastoma multiforme, and LP-284, in a Phase 1 trial for relapsed or refractory non-Hodgkin’s lymphoma and other solid tumors), an antibody-drug conjugate program, and programs in CNS and brain cancers. All of the programs are being developed using RADR(R) to streamline discovery and development timelines. The company is also engaged in research partnerships with academic institutions and global trial networks.

Clinical updates from the HARMONIC(TM) trial are expected through the second half of 2025 as enrollment progresses.

For more information, visit the company’s website at www.LanternPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN

• ONAR’s technology-first approach combines its proprietary AI platform with strategic agency acquisitions to deliver measurable marketing results for middle-market companies
• Recent board appointment of advertising innovator Jon Bond reinforces ONAR’s positioning at the intersection of creativity and technology in the evolving martech landscape
• The company’s integrated model leverages AI automation across performance media, SEO, and healthcare marketing through its network of agencies

The marketing technology sector finds itself at a crossroads that extends far beyond the typical innovation cycle. As adtech companies scramble to incorporate artificial intelligence into their offerings, launching everything from automated creative platforms to machine learning optimization tools, a critical distinction is emerging between organizations that deploy AI strategically versus those that implement it reactively. The difference lies not in the sophistication of the technology itself, but in how deeply AI capabilities are woven into core business operations.

The reality is that most current AI deployments follow a fragmented approach. Companies introduce AI capabilities piecemeal: optimization suggestions in one area, automated reporting in another, predictive analytics as a separate module. While each component may deliver incremental value, this scattered implementation prevents AI from reaching its full potential as a learning system that improves through interconnected data flows.

This fragmentation has opened the door for companies that recognize a key market insight: the most valuable implementations are those that create unified intelligence across the entire marketing ecosystem, where insights from one area continuously inform and enhance performance in others.

That’s a sweet spot for ONAR Holding Corp. (OTCQB: ONAR), a technology-first network of marketing agencies that has positioned itself nicely within this AI-driven revolution in adtech.

Integrated AI Architecture Delivers Real Performance

ONAR’s competitive advantage lies in understanding what many adtech companies miss: AI’s transformational power comes from system-wide integration, not isolated features. The company’s model blends strategic services, AI-driven insights and scalable execution to give companies the tools and support they need to scale quickly and smartly – something that larger agencies can’t always do with smaller companies.

Originally developed by ONAR’s flagship agency Storia, Cortex creates closed-loop feedback cycles essential for meaningful AI impact. The platform ingests real-time first-party data across campaign touchpoints, analyzes audience response and creative performance in context, then feeds insights back into the system to improve subsequent decisions and activations.

Currently, Storia clients access Cortex at no additional cost, demonstrating ONAR’s commitment to treating AI as core infrastructure rather than an expensive add-on. This philosophy aligns with industry insights suggesting that companies treating AI as essential infrastructure will be best positioned to lead in the evolving adtech landscape.

Strategic Leadership Reinforces AI Vision

ONAR’s recent appointment of Jon Bond to its Board of Directors signals serious intent to accelerate its AI-driven growth strategy. Bond brings decades of experience from the intersection of creativity and technology, having co-founded Kirshenbaum & Bond, pioneered programmatic media through ventures like Varick, and served as CEO of Big Fuel before its acquisition by Publicis.

“I have spent my career at the intersection of creativity and technology, building businesses that challenge current industry norms,” Bond stated in announcing his appointment. His experience with AI-powered media company Inuvo and his nomination for the 2025 Advertising Hall of Fame underscore his understanding of how artificial intelligence can transform marketing effectiveness.

Bond’s appointment addresses the critical need for leadership that understands both creative strategy and technological implementation, a combination essential for successful AI integration in agency environments.

End-to-End Integration Creates Competitive Advantage

ONAR’s strategy extends beyond technological development to deliver AI-driven adtech that matters to all businesses. The company’s portfolio, including Storia (performance marketing and SEO) and Of Kos (full-service marketing for the healthcare industry), creates an interconnected system where each agency component communicates with the others, enabling Cortex to deliver system-wide intelligence rather than isolated optimizations.

This integrated approach enables dynamic performance optimization that defines next-generation adtech. Cortex can analyze audience response patterns across Storia’s performance campaigns, using all the information available to create cross-pollination of insights impossible in siloed systems.

ONAR Labs, the company’s dedicated technology development division, ensures continuous innovation through its team of data scientists, engineers, and industry experts working alongside professionals. This structure keeps technology development grounded in real-world client needs rather than theoretical applications.

Market Positioning and Growth Potential

The timing of ONAR’s AI-first approach appears strategically sound. It’s arguable that marketers who can effectively combine AI’s capabilities with human expertise will have a clear advantage in 2025, crafting campaigns that are both scalable and deeply resonant. Organizations that successfully integrate AI across their operations are positioning themselves to capture significant competitive advantages in efficiency, speed, and revenue generation.

ONAR’s focus on middle-market and growth-stage companies addresses a market segment that often lacks access to enterprise-level marketing technology. As AI adoption accelerates across the marketing industry, this creates substantial growth opportunities for companies that can deliver sophisticated AI capabilities at accessible price points.

For more information, visit the company’s website at www.ONAR.com.

NOTE TO INVESTORS: The latest news and updates relating to ONAR are available in the company’s newsroom at https://ibn.fm/ONAR